2015/09 – Present Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences.
2014/12 – 2015/08 Pharmaron (Beijing) New Drug Technology Co., Ltd, Process R&D
2006/09 – 2014/06 Lanzhou University, Organic Chemistry, M.S. & Ph.D. (combined program)
2002/09 – 2006/06 Lanzhou University, Chemistry, B.S.
Main research areas and achievements:
1. Over one hundred structurally novel lappaconitine derivatives were synthesized, and the lead compound CAM68 was identified through screening. CAM68 exhibited oral efficacy comparable to that of lappaconitine, while showing significantly improved safety, metabolic stability in vivo, and bioavailability. A detailed structure–activity relationship (SAR) was established. Mechanistic studies revealed that CAM68 exerts use-dependent inhibitory effects primarily through the Nav1.5 channel, with moderate inhibition of the late sodium current, classifying it as a Class Ic antiarrhythmic agent. Related research findings have been filed for international patent application. The development of CAM68 provides a solid material foundation for the creation of innovative antiarrhythmic drugs with independent intellectual property rights.
2. The xanthohumol derivative CAM12203 was synthesized and found to ameliorate acute liver injury by binding to DGKζ and blocking the DGKζ–STAT3 pathway, thereby inhibiting IL-1β transcription in macrophages. This study facilitates the development and application of CAM12203 and its potential derivatives, and offers a novel therapeutic target for acute liver failure.
3. Structure-based design, virtual screening, and synthesis were carried out on the natural products ES3 and ES7 derived from Euphorbia sororia. Among the obtained derivatives, more than ten exhibited superior anti-multidrug-resistant tumor activity compared to the positive control. Among them, derivative ES-D12 showed the strongest activity with low cytotoxicity, and was found to significantly inhibit the efflux of doxorubicin and rhodamine in drug-resistant cells in a concentration-dependent manner. A detailed structure–activity relationship was subsequently summarized based on these findings.
Honors and awards：
Outstanding Staff Award, 2019
Representative articles :
1. Miao, Y., Lin, T., Wang, B., Xu, J., Li, C., Li, Z., Zhang, X., Zhou, C., Aji, T., Tan, M. and Aisa, H.A., Macrophage DGKζ-mediated phosphatidic acid remodeling aggravates acute liver failure. Acta Pharmaceutica Sinica B. 2025, 15, 4078-4095. (Co-first author)
2. Maimaitijiang, A., Wang, B., Yang, H., Tang, D., Liu, Y. and Aisa, H.A. Discovery of a novel highly potent and low-toxic jatrophane derivative enhancing the P-glycoprotein-mediated doxorubicin sensitivity of MCF-7/ADR cells. European Journal of Medicinal Chemistry, 2022, 244, 114822. (Co-first author)
3. Ajiaikebaier, D., Li, Z., Lin, T., Sun, X., Wang, B. and Li, J. Synthesis of pyranochalcone derivatives and their inhibitory effect on NF-κB activation. Bioorganic & Medicinal Chemistry Letters, 2021, 42, 128042. (Corresponding author)
4. Wang, B., Zhao, B., Xue, W., Sagdullaev, S. S., and Zhao, J. Synthesis and Assessment of Antiarrhythmic Properties of C4-Amino Derivatives of Lappaconitine. Chemistry of Natural Compounds, 2026, 62(2), 343-348.
5. Chen, H., Zhang, H., Niu, C., Wang, B., Gao, B., Liu, Z., Yao, G. and Aisa, H.A. Anacyphrethines A and B as potent analgesics: Multiple ion channel inhibitors with an unprecedented chemical architecture. Acta Pharmaceutica Sinica B. 2025, 15, 3725-3737.
6. Turgunov, D., Nie, L., Nasrullaev, A., Murtazaeva, Z., Wang, B., Kholmurodova, D., Kuryazov, R., Zhao, J., Bozorov, K. and Aisa, H.A. Synthesis of Novel 7-Phenyl-2, 3-Dihydropyrrolo [2, 1-b] Quinazolin-9 (1 H)-ones as Cholinesterase Inhibitors Targeting Alzheimer’s Disease Through Suzuki–Miyaura Cross-Coupling Reaction. Molecules, 2025, 30(13), 2791.
7. Li, Y., Wang, B., Niu, C. and Hou, X. Quantitative Structure-Activity Relationship and Molecular Docking of Aurone Inhibitors. Chemistry, 2022, 85(6), 728-735.
8. Zhang, C., Wang, B., Aibibula, P., Zhao, J. and Aisa, H.A. Enantioselective construction of substituted pyridine and a seven-membered carbocyclic skeleton: biomimetic synthesis of (−)-rupestine D,(−)-guaipyridine,(−)-epiguaipyridine, and (−)-cananodine and their stereoisomers. Organic & Biomolecular Chemistry, 2021, 19(32), 7081-7084.
9. Aibibula, P., Yusuf, A., Zhao, J., Wang, B., Huang, G. and Aisa, H.A. Synthesis of (±)-rupestine A and (±)-rupestine J, structural reassignment of rupestine A via ECD analysis. Chemical Papers, 2021, 75(10), 5599-5603.
10. Ablajan, N., Zhao, B., Zhao, J, Wang, B, Sagdullaev, S. and Aisa, H.A. Diterpenoid alkaloids from Aconitum barbatum var. puberulum Ledeb. Phytochemistry, 2021, 181, p.112567.
Representative patents :
1. Wang Bianlin, Zhao Bo, Zhao Jiangyu, Xue Wenjuan, Haji Akber Aisa, Shamansur Sagdullaev. Salt of a lappaconitine derivative, and preparation method and use thereof. Patent No.: ZL 2025 1 0114058.7
2. Wang Bianlin, Dilidaer Ajiaikebaier, Sun Xinyu, Li Zuopeng, Li Jingya, Haji Akber Aisa. A xanthohumol derivative and preparation method and use thereof. Patent No.: ZL 2020 1 0957790.8
3. Haji Akber Aisa, Yang Hequn, Wang Bianlin, Tang Dan, Ayitila Maimaitijiang. A jatrophane-type diterpene derivative and preparation method and use thereof. Patent No.: 202110670348.1
4. Haji Akber Aisa, Zhang Cun, Wang Bianlin. A method for preparing guaipyridine-type sesquiterpene alkaloids. Patent No.: 202110684439.0
5. Haji Akber Aisa, Shen Jingshan, Shamansur Sagdullaev, Murat Yunusov, Zhao Qingjie, Wang Bianlin, Alimujiang Sadekuofu, Hainimu Siamuxi, et al. A lappaconitine derivative and preparation method and use thereof. (ZL 2020 1 1276843.6, granted as Chinese patent, Eurasian patent, and Uzbekistan patent)
Research area：
Focusing on drug discovery-oriented structural modification of natural products, primarily including the development of antiarrhythmic agents from diterpenoid alkaloids and the study of anti-multidrug-resistant tumor activity of macrocyclic diterpene derivatives.
